Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
After approval of the latest cellular therapy for non-Hodgkin lymphoma, the big challenge is how to extend it to common solid tumors.
Half of patients treated with Breyanzi experienced complete remission, and a majority of these responses were durable.
Here’s a list of the approved drugs to treat lyphoma including Non-Hodgkin lymphoma and Hodgkin lymphoma. Click on any of the medicat...
A former labor and delivery nurse, Lindy Sledge, 62, lives with her family in Franklin, Kentucky. She has mantle cell lymphoma.
Yescarta led to complete remission in people with advanced non-Hodgkin lymphoma.
A dedicated student of jiujitsu, Avie Barron, 36, was diagnosed with non-Hodgkin lymphoma in her right lung.
Lymphoma is a cancer that begins in the cells of the lymph system.
World Lymphoma Awareness Day (WLAD) is held on September 15 every year and is a day dedicated to raising awareness of lymphoma.
More than a third of people treated with Monjuvi plus Revlimid experienced complete remission.
Tecartus led to durable remission in a majority of participants in a Phase II study.
The popular weed killer has been linked to tens of thousands of cases of non–Hodgkin lymphoma.
The SADAL study showed a 29% response rate for treatment-experienced people with DLBCL.
A study showed a 69% response rate for patients whose cancer carries the targeted mutation.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.